Bavarian Nordic has crashed out of the respiratory syncytial virus (RSV) vaccine race, with a phase III failure in older adults sending the company’s plans—and stock price—into a tailspin.
[Fierce Biotech]
Home Newsletters Immunology of Infectious Disease News ‘An Unexpected Outcome’: Bavarian Nordic Crashes Out of RSV Race as Vaccine...
